We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

First-Ever Saliva-Based Concussion Test to Be Available in 2023

By LabMedica International staff writers
Posted on 21 Nov 2022
Print article
Image: The Clarifi mTBI saliva test collection device (Photo courtesy of Quadrant Biosciences)
Image: The Clarifi mTBI saliva test collection device (Photo courtesy of Quadrant Biosciences)

According to the (CDC), 1.6 to 3.8 million athletes will experience a sports-related mild traumatic brain injury (mTBI) or concussion each year. Despite increased public awareness, clinical guidelines still rely on subjective symptom scales to diagnose and manage concussions. Furthermore, there are currently no biological tests to diagnose mTBI. Now, new research has revealed that biomarkers found in saliva may distinguish mTBI and parallel symptom recovery.

By analyzing brain derived biomarkers found in saliva, scientists at Quadrant Biosciences (Syracuse, NY, USA), in collaboration with Penn State (Hershey, PA, USA) and the State University of New York (New York, NY, USA), have developed a novel diagnostic test for concussion. These biomarkers can confirm mTBI when run through Quadrant’s proprietary artificial intelligence platform. The Clarifi mTBI Saliva Test being developed by Quadrant uses small non-coding RNAs found in the saliva to help diagnose concussions. The U.S. Patent and Trademark Office (USPTO) has awarded the company and its academic partners with a patent for the analysis and prediction of mTBI and concussion symptoms. Quadrant has started discussions about potentially licensing this technology to third-parties, and the test is expected to be available in late 2023.

"Our motivation for developing this technology was to prevent further harm to the kids, athletes, and adults who experience mild, moderate, or repetitive head impacts," said Dr. Frank Middleton, PhD, Professor at SUNY Upstate Medical University, who led the patented research. "While most of the field has focused on peripheral blood measures, for the past decade we worked extensively to establish the utility of quantifying small RNA molecules in saliva as predictors of concussion or long-lasting symptoms from head impacts."

"As a pediatrician who provides medical care for children and teens with concussion, I am excited by the potential of this technology to improve the way clinicians manage this common injury. A saliva-based test for concussion could provide a novel addition to the physician toolbox," said Dr. Steve Hicks, MD, PhD, at Penn State College of Medicine, who was also among the ones to lead the patented research.

Related Links:
Penn State
Quadrant Biosciences
State University of New York 

Platinum Supplier
Hormonal Test
Endocrine Array
Fecal Occult Blood Test
Fecal Occult Blood (iFOB) Neo
3 & 5-Part All-In-One Auto Hematology Analyzer
DNA/RNA Extraction Buffer
Enzymatic DNA/RNA Extraction Buffer

Print article


Clinical Chem.

view channel
Image: Equivalence of Genetically Elevated LDL and Lipoprotein(a) on Myocardial Infarction (Photo courtesy of Viborg Regional Hospital)

Familial Hypercholesterolemia Patients With ACD Have Elevated Lipoprotein(a)

Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein (LDL cholesterol), in the blood and early cardiovascular... Read more


view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more


view channel
Image: Breast cancer spread uncovered by new molecular microscopy (Photo courtesy of Wellcome Sanger Institute)

New Molecular Microscopy Tool Uncovers Breast Cancer Spread

Breast cancer commonly starts when cells start to grow uncontrollably, often due to mutations in the cells. Overtime the tumor becomes a patchwork of cells, called cancer clones, each with different mutations.... Read more


view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.